Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Department of Diagnosis Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hum Cell. 2022 Jul;35(4):1290-1297. doi: 10.1007/s13577-022-00721-5. Epub 2022 Jun 2.
Synovial sarcoma (SS) is a rare and aggressive mesenchymal malignancy driven by a unique chromosomal translocation that generates the expression of the SS18:SSX fusion protein. It occurs at almost any anatomical site and most commonly in young adults. The standard curative treatment for primary SS is a wide surgical resection combined with radiotherapy and/or neoadjuvant chemotherapy. The prognosis of SS varies among patients, with the 5 years survival rate ranging from 50 to 60% in adults and 90% in children. Although patient-derived cell lines are a useful resource for the development of new therapies, only a few are available from public cell banks. Therefore, this study aimed to establish and characterize a novel SS cell line. We successfully established a novel cell line, NCC-SS5-C1, harboring an SS18-SSX1 fusion gene. NCC-SS5-C1 cells demonstrated constant growth and invasion ability. We performed integrative drug screening using eight SS cell lines, including NCC-SS5-C1 cells, and examined the response spectrum of existing anticancer agents. We conclude that NCC-SS5-C1 is a useful resource for studying SS.
滑膜肉瘤 (SS) 是一种罕见且侵袭性的间叶性恶性肿瘤，由独特的染色体易位驱动，产生 SS18:SSX 融合蛋白的表达。它几乎可以发生在任何解剖部位，最常见于年轻人。原发性 SS 的标准治愈性治疗是广泛的手术切除，结合放疗和/或新辅助化疗。SS 患者的预后各不相同，成年人的 5 年生存率为 50%至 60%，儿童为 90%。虽然患者来源的细胞系是开发新疗法的有用资源，但只有少数可从公共细胞库获得。因此，本研究旨在建立和表征一种新型 SS 细胞系。我们成功建立了一种新型细胞系 NCC-SS5-C1，其携带 SS18-SSX1 融合基因。NCC-SS5-C1 细胞表现出持续的生长和侵袭能力。我们使用包括 NCC-SS5-C1 细胞在内的八种 SS 细胞系进行了综合药物筛选，并检查了现有抗癌药物的反应谱。我们得出结论，NCC-SS5-C1 是研究 SS 的有用资源。
